First-in-human, phase 1 dose escalation study of SL-279252, a hexameric PD1-Fc-OX40L fusion protein, in patients with advanced solid tumors and lymphoma.
Saved in:
| Title: | First-in-human, phase 1 dose escalation study of SL-279252, a hexameric PD1-Fc-OX40L fusion protein, in patients with advanced solid tumors and lymphoma. |
|---|---|
| Authors: | Johnson M; Sarah Cannon Research Institute, Nashville, TN, USA., Hong D; MD Anderson Cancer Center, Houston, TX, USA., Braña I; Vall d'Hebron Institute of Oncology, Barcelona, Spain., Schöffski P; University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium., Galvao V; Vall d'Hebron Institute of Oncology, Barcelona, Spain., Rangwala F; Shattuck Labs, Durham, NC, 27709, USA., Ma B; Shattuck Labs, Durham, NC, 27709, USA., Hernandez R; Shattuck Labs, Durham, NC, 27709, USA., Kamat A; Shattuck Labs, Durham, NC, 27709, USA., Kato K; Shattuck Labs, Durham, NC, 27709, USA., Schreiber TH; Shattuck Labs, Durham, NC, 27709, USA., Pandite L; Shattuck Labs, Durham, NC, 27709, USA. lpandite@shattucklabs.com., Siu LL; Princess Margaret Cancer Center, Toronto, Canada. |
| Source: | Investigational new drugs [Invest New Drugs] 2025 Apr; Vol. 43 (2), pp. 284-292. Date of Electronic Publication: 2025 Mar 05. |
| Publication Type: | Journal Article; Clinical Trial, Phase I; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 40042547 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: First-in-human, phase 1 dose escalation study of SL-279252, a hexameric PD1-Fc-OX40L fusion protein, in patients with advanced solid tumors and lymphoma. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Johnson+M%22">Johnson M</searchLink>; Sarah Cannon Research Institute, Nashville, TN, USA.<br /><searchLink fieldCode="AU" term="%22Hong+D%22">Hong D</searchLink>; MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Braña+I%22">Braña I</searchLink>; Vall d'Hebron Institute of Oncology, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Schöffski+P%22">Schöffski P</searchLink>; University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium.<br /><searchLink fieldCode="AU" term="%22Galvao+V%22">Galvao V</searchLink>; Vall d'Hebron Institute of Oncology, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Rangwala+F%22">Rangwala F</searchLink>; Shattuck Labs, Durham, NC, 27709, USA.<br /><searchLink fieldCode="AU" term="%22Ma+B%22">Ma B</searchLink>; Shattuck Labs, Durham, NC, 27709, USA.<br /><searchLink fieldCode="AU" term="%22Hernandez+R%22">Hernandez R</searchLink>; Shattuck Labs, Durham, NC, 27709, USA.<br /><searchLink fieldCode="AU" term="%22Kamat+A%22">Kamat A</searchLink>; Shattuck Labs, Durham, NC, 27709, USA.<br /><searchLink fieldCode="AU" term="%22Kato+K%22">Kato K</searchLink>; Shattuck Labs, Durham, NC, 27709, USA.<br /><searchLink fieldCode="AU" term="%22Schreiber+TH%22">Schreiber TH</searchLink>; Shattuck Labs, Durham, NC, 27709, USA.<br /><searchLink fieldCode="AU" term="%22Pandite+L%22">Pandite L</searchLink>; Shattuck Labs, Durham, NC, 27709, USA. lpandite@shattucklabs.com.<br /><searchLink fieldCode="AU" term="%22Siu+LL%22">Siu LL</searchLink>; Princess Margaret Cancer Center, Toronto, Canada. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%228309330%22">Investigational new drugs</searchLink> [Invest New Drugs] 2025 Apr; Vol. 43 (2), pp. 284-292. <i>Date of Electronic Publication: </i>2025 Mar 05. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Clinical Trial, Phase I; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer%22">Springer </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>8309330 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1573-0646 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201676997%22">01676997 </searchLink><i>NLM ISO Abbreviation: </i>Invest New Drugs <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40042547 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1007/s10637-025-01518-7 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 284 Titles: – TitleFull: First-in-human, phase 1 dose escalation study of SL-279252, a hexameric PD1-Fc-OX40L fusion protein, in patients with advanced solid tumors and lymphoma. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Johnson M – PersonEntity: Name: NameFull: Hong D – PersonEntity: Name: NameFull: Braña I – PersonEntity: Name: NameFull: Schöffski P – PersonEntity: Name: NameFull: Galvao V – PersonEntity: Name: NameFull: Rangwala F – PersonEntity: Name: NameFull: Ma B – PersonEntity: Name: NameFull: Hernandez R – PersonEntity: Name: NameFull: Kamat A – PersonEntity: Name: NameFull: Kato K – PersonEntity: Name: NameFull: Schreiber TH – PersonEntity: Name: NameFull: Pandite L – PersonEntity: Name: NameFull: Siu LL IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 04 Text: 2025 Apr Type: published Y: 2025 Identifiers: – Type: issn-electronic Value: 1573-0646 Numbering: – Type: volume Value: 43 – Type: issue Value: 2 Titles: – TitleFull: Investigational new drugs Type: main |
| ResultId | 1 |
